FDA grants QIDP and Fast Track Designations to CD101 IV for the treatment of candidemia
11 May 2015 | By Victoria White
Cidara Therapeutics has announced that the FDA has designated the Company’s lead antifungal product candidate, CD101 IV, as a QIDP with Fast Track status...